INTRA-CELLULAR THERAPI

Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock

03 1 2022 16:01:00 提供 Nasdaq GlobeNewswire

Intra-Cellular Therapies to Present at the 40th Annual J.P. Morgan Healthcare Conference

03 1 2022 08:00:01 提供 Nasdaq GlobeNewswire

Intra-Cellular Therapies Announces U.S. FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression in Adults

20 12 2021 06:47:22 提供 Nasdaq GlobeNewswire

Intra-Cellular Therapies Mourns the Passing of Director, Dr. Richard Lerner

06 12 2021 16:01:00 提供 Nasdaq GlobeNewswire

Intra-Cellular Therapies Reports Third Quarter 2021 Financial Results and Provides Corporate Update

09 11 2021 07:30:01 提供 Nasdaq GlobeNewswire

Intra-Cellular Therapies to Host Third Quarter 2021 Financial Results Conference Call and Webcast

02 11 2021 08:00:03 提供 Nasdaq GlobeNewswire

Intra-Cellular Therapies Announces Amended Start Time to Virtual Event on Wednesday, October 20

18 10 2021 08:00:00 提供 Nasdaq GlobeNewswire

Intra-Cellular Therapies to Host a Virtual Event to Feature Highlights of Several of its Development Programs

08 10 2021 08:00:00 提供 Nasdaq GlobeNewswire

Intra-Cellular Therapies Announces Publication of Lumateperone Pivotal Phase 3 Study in Bipolar Depression in The American Journal of Psychiatry

27 9 2021 07:30:00 提供 Nasdaq GlobeNewswire

Intra-Cellular Therapies to Present at the 2021 Cantor Virtual Global Healthcare Conference

22 9 2021 08:00:01 提供 Nasdaq GlobeNewswire

Intra-Cellular Therapies Announces Publications Highlighting Beneficial Effects of Phosphodiesterase Type I Inhibition with Lenrispodun (ITI-214) on Cardiovascular Function in Patients with Heart Failure and in Models of Accelerated Aging

20 9 2021 07:30:00 提供 Nasdaq GlobeNewswire

Intra-Cellular Therapies to Present at the Canaccord Genuity 41st Annual Growth Conference

10 8 2021 08:00:02 提供 Nasdaq GlobeNewswire

Intra-Cellular Therapies Reports Second Quarter 2021 Financial Results and Provides Corporate Update

09 8 2021 07:30:00 提供 Nasdaq GlobeNewswire

Intra-Cellular Therapies to Host Second Quarter 2021 Financial Results Conference Call and Webcast

02 8 2021 08:00:02 提供 Nasdaq GlobeNewswire

CAPLYTA® (lumateperone) Schizophrenia Safety and Tolerability Profile Published in the Journal, International Clinical Psychopharmacology

07 6 2021 08:00:02 提供 Nasdaq GlobeNewswire

Intra-Cellular Therapies to Present at Two Upcoming Investor Conferences

26 5 2021 08:00:02 提供 Nasdaq GlobeNewswire

Intra-Cellular Therapies Reports First Quarter 2021 Financial Results and Provides Corporate Update

10 5 2021 07:30:00 提供 Nasdaq GlobeNewswire

Intra-Cellular Therapies to Present at Two Upcoming Investor Conferences

05 5 2021 08:00:01 提供 Nasdaq GlobeNewswire

Intra-Cellular Therapies to Host First Quarter 2021 Financial Results Conference Call and Webcast

04 5 2021 08:00:01 提供 Nasdaq GlobeNewswire

Intra-Cellular Therapies Announces FDA Acceptance of CAPLYTA® (lumateperone) sNDAs for the Treatment of Bipolar Depression

03 5 2021 07:30:00 提供 Nasdaq GlobeNewswire